ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 958,18
0,55%
Dow Jones
38 225,66
0,00%
DAX
17 972,95
0,38%
Brent Oil
84,105
0,57%
Bitcoin
59 210,64
0,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. ADC Therapeutics SA (ADCT)

  7. ADC Therapeutics SA (ADCT) Actualités

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:ADCT
DateHeureSourceTitreSymboleSociété
01/05/202422h05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
01/05/202413h00GlobeNewswire Inc.ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024NYSE:ADCTADC Therapeutics SA
04/04/202413h00GlobeNewswire Inc.ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaNYSE:ADCTADC Therapeutics SA
03/04/202413h00GlobeNewswire Inc.ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024NYSE:ADCTADC Therapeutics SA
13/03/202412h03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNYSE:ADCTADC Therapeutics SA
13/03/202412h00GlobeNewswire Inc.ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/03/202413h15GlobeNewswire Inc.ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitNYSE:ADCTADC Therapeutics SA
06/03/202413h00GlobeNewswire Inc.ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024NYSE:ADCTADC Therapeutics SA
05/03/202423h45GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingNYSE:ADCTADC Therapeutics SA
05/03/202415h15Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
27/02/202413h00GlobeNewswire Inc.ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:ADCTADC Therapeutics SA
04/01/202413h15GlobeNewswire Inc.ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
04/01/202413h00GlobeNewswire Inc.ADC Therapeutics Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
03/01/202402h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
19/12/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:ADCTADC Therapeutics SA
18/12/202322h25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
12/12/202311h15GlobeNewswire Inc.ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)NYSE:ADCTADC Therapeutics SA
20/11/202308h40PR Newswire (US)Sobi to present new data at ASH 2023 Annual MeetingNYSE:ADCTADC Therapeutics SA
15/11/202309h00GlobeNewswire Inc.Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsNYSE:ADCTADC Therapeutics SA
07/11/202313h15GlobeNewswire Inc.ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
07/11/202313h00GlobeNewswire Inc.ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/11/202313h00GlobeNewswire Inc.ADC Therapeutics to Participate in the Jefferies London Healthcare ConferenceNYSE:ADCTADC Therapeutics SA
02/11/202315h10GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
24/10/202313h00GlobeNewswire Inc.ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023NYSE:ADCTADC Therapeutics SA
04/10/202310h00GlobeNewswire Inc.Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSONYSE:ADCTADC Therapeutics SA
05/09/202313h00GlobeNewswire Inc.ADC Therapeutics to Participate in September Investor ConferencesNYSE:ADCTADC Therapeutics SA
31/08/202301h32GlobeNewswire Inc.ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)NYSE:ADCTADC Therapeutics SA
08/08/202313h00GlobeNewswire Inc.ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
01/08/202313h00GlobeNewswire Inc.ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NYSE:ADCTADC Therapeutics SA
24/07/202313h21GlobeNewswire Inc.Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaNYSE:ADCTADC Therapeutics SA
 Showing the most relevant articles for your search:NYSE:ADCT

Dernières Valeurs Consultées

EU
CS
Axa
NASDAQ
GOOGL
Alphabet
EU
SGO
Cie de SaintGobain
EU
MC
Lvmh Moet Hennessy Louis...
EU
BEL20
Bel 20
EU
VK
Vallourec
NYSE
NKE
Nike
NYSE
KO
Coca Cola
EU
LR
Legrand
EU
RI
Pernod Ricard
NASDAQ
AAPL
Apple
EU
PX4
SBF 120
NASDAQ
AMZN
Amazon.com
EU
GLE
Societe Generale
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés